Welcome to our dedicated page for eXoZymes SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
eXoZymes Inc. SEC filings document a Nevada biotechnology issuer with common stock listed on the Nasdaq Capital Market under the symbol EXOZ. The filing record is centered on Form 8-K Item 8.01 current reports that furnish investor presentations, press releases, and exhibit materials.
These filings disclose company communications about the exozyme cell-free biomanufacturing platform, NCTx business materials, NCT production scale-up, commercial-readiness updates, and capital-markets presentation materials associated with securities offering activity. They also identify the registered common stock class, exchange listing, exhibit filings, and formal signatures required under Exchange Act reporting.
eXoZymes Inc. is raising approximately $5.33 million through an underwritten public unit offering of common stock and warrants priced at $18.00 per unit. Each unit includes two shares and one warrant, with the offering made off an effective Form S-3 shelf registration.
The underwriter has a 45-day option to buy additional units, which could lift gross proceeds to $6.13 million before fees. Warrants become exercisable one year after the offering at $11.24 per share, can be redeemed once the stock trades at or above $17.98 for twenty out of thirty trading days, and include a reset feature that can cut the exercise price to $0.001 if eXoZymes sells stock or convertible securities below $8.99 within twelve months, subject to strict holding-period conditions for original investors.
Net proceeds, after underwriting commissions of about $0.37 million and estimated offering expenses of $0.25 million, are earmarked to advance the company’s N-trans-caffeoyltyramine (NCT) programs, other research and development, and general corporate and working capital needs.
eXoZymes Inc. is offering 592,270 shares of common stock and 296,135 warrants as units (two shares plus one warrant) pursuant to a prospectus supplement. Units are priced at $18.00 per unit; the offering includes a 45-day 15% over-allotment option. Each Warrant is exercisable beginning one year after the offering at $11.24 and expires five years after issuance, with a one-time exercise-price reset provision to $0.001 under specified conditions and a redemption feature at $0.01 per Warrant when the share price meets the stated trigger. Net proceeds are estimated at approximately $4,704,300 (or $5,447,891 if the over-allotment is exercised) to be used for developing the Company’s NCT program, next-in-line products, R&D, working capital and capital expenditures.
eXoZymes Inc. is conducting a proposed underwritten offering of units, each consisting of two shares of common stock and one warrant, under a preliminary prospectus supplement dated June 4, 2026. The filing states 8,478,992 shares outstanding and a public float value of $15,165,341 based on 8,478,992 shares and a per-share price of $11.70 as of April 10, 2026. MDB Capital Holdings is the largest pre-offering holder with 4,136,426 shares (representing 47.79%).
The units pair two common shares with one warrant exercisable beginning one year after issuance and expiring five years after issuance, subject to a potential exercise-price reset to $0.001 if the company issues equity at a lower price within one year. Warrants are redeemable for $0.01 under specified trading-price conditions. The offering includes a 45-day, up-to-15% overallotment option, a 7% underwriting discount, and underwriter warrants equal to 10% of shares and underlying securities sold.
eXoZymes Inc. is offering units consisting of two shares of common stock and one common-stock purchase warrant, together with separate Warrants exercisable for one share each. The prospectus supplement sets terms including a two-year warrant term, potential issuer call/redemption mechanics, and a 45-day 15% over-allotment option.
The filing discloses that MDB Capital Holdings beneficially holds 4,136,426 shares (47.79%) and that Lucid Capital Markets will act as the FINRA-qualified independent underwriter for a $175,000 fee. The company reports a public float of $15,165,341 based on 8,478,992 shares and a reference price of $11.70 as of April 10, 2026. Use of proceeds is stated for NCT program development, R&D, working capital and general corporate purposes.
eXoZymes Inc. reported another pre-revenue quarter for the three months ended March 31, 2026, with a net loss of $2.37 million, wider than the $1.86 million loss a year earlier. Higher research and development spending, which nearly doubled to $1.12 million, and increased compensation costs drove the larger loss.
Cash and cash equivalents fell to $1.44 million after operating cash outflows of $1.52 million, leaving working capital of about $0.51 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new funding and is pursuing grants and a proposed public equity offering of approximately $15 million under an existing $50 million shelf registration.
eXoZymes Inc. filed a current report to share an updated investor presentation dated May 7, 2026. The presentation is being provided to potential underwriters, other offering participants, and investors in connection with a proposed public offering of the company’s securities.
The report lists the presentation as Exhibit 99.1 and includes a cover page interactive data file as Exhibit 104. eXoZymes is a Nevada corporation whose common stock trades on the Nasdaq Capital Market under the symbol EXOZ.
eXoZymes Inc.
EXOZYMES INC. Chief Scientific Officer Korman Tyler Paz reported small open-market sales of company common stock. On April 8, Paz sold 750 shares at an average price of $10.0406 per share, followed by another 750 shares on April 9 at $10.525 per share.
Across the two days Paz sold a total of 1,500 shares and now directly holds 729,123 shares of EXOZYMES INC. common stock. The transactions are classified as open-market sales of non-derivative common stock.
eXoZymes Inc. filed a preliminary prospectus supplement to sell shares of its common stock under a shelf registration (Registration No. 333-292781). The offering size and per-share price are redacted in this excerpt. The lead underwriter, MDB Capital, is affiliated with a 47.79% holder, creating a FINRA Rule 5121 conflict; a qualified independent underwriter will participate.
The company states it will use net proceeds to advance its NCT program, related nutraceutical commercialization and R&D, and for general corporate purposes. The filing discloses pilot-scale NCT production at >99% purity and commercial scale-up plans, but many financial and offering specifics are redacted in the provided excerpt.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received equity-based compensation on April 1, 2026. He was granted stock options for 146,437 shares of common stock at an exercise price of $9.49 per share and a restricted stock award of 62,759 shares.
The restricted shares vest quarterly at 3,923 shares, with 15,689 shares vesting immediately and a final 3,917-share installment scheduled on April 1, 2029. The options vest monthly at 3,050 shares, with 36,609 shares vesting immediately and a final 3,078-share installment also on April 1, 2029.
After these awards, Perriman directly holds 62,759 common shares from the restricted stock grant and 146,437 stock options, all granted as compensation rather than through open-market buying or selling.